ABL1 and acute lymphoblastic leukemia: The success of TKIs as a precision medicine approach for targeting BCR:ABL1 in CML and Ph+ ALL launched a new era of discovery into targeted cancer therapies (Sawyers, 2003; Rossari et al., 2018).